Embiosys Inc.
Publicly observedNorth Andover, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | North Andover | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Embiosys Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | Q9PEK2FTD4H6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant17 Sept 2025Publicly observed
NIH SBIR/STTR award: CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
USD 870,482.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant17 Sept 2025Publicly observed
NIH SBIR/STTR award: CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
USD 1,379,442.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2024Publicly observed
NIH SBIR/STTR award: DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)
USD 188,875.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.